Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and <i>JAK2</i> V617F mutation despite discontinuation of treatment.

Hatzimichael, Eleftheria; Lagos, Konstantinos; Vassou, Amalia; Gougopoulou, Dora; Papoudou-Bai, Alexandra; Briasoulis, Evangelos

Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment.

Hatzimichael, Eleftheria; Lagos, Konstantinos; Vassou, Amalia; Gougopoulou, Dora; Papoudou-Bai, Alexandra; Briasoulis, Evangelos.

Afiliación

Hatzimichael E; Department of Hematology, University of Ioannina, 45110 Ioannina, Greece; Thomas Jefferson University, Computational Medicine Center, Sidney Kimmel Medical College, Philadelphia, PA 19107, USA.
Lagos K; Department of Hematology, University of Ioannina, 45110 Ioannina, Greece.
Vassou A; Department of Hematology, University of Ioannina, 45110 Ioannina, Greece.
Gougopoulou D; Department of Hematology, University of Ioannina, 45110 Ioannina, Greece.
Papoudou-Bai A; Department of Pathology, University Hospital of Ioannina, 45500 Ioannina, Greece.
Briasoulis E; Department of Hematology, University of Ioannina, 45110 Ioannina, Greece.

Mol Clin Oncol ; 5(1): 23-26, 2016 Jul.

Article en En | MEDLINE | ID: mdl-27330758

Palabras clave

JAK2 V617F; del(5q); lenalidomide; myelodysplastic syndrome

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Mol Clin Oncol Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google